Cost-Utility Analysis of Pazopanib Verse Sunitinib as First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC) iN Spain.

التفاصيل البيبلوغرافية
العنوان:	Cost-Utility Analysis of Pazopanib Verse Sunitinib as First-Line Treatment of Metastatic Renal Cell Carcinoma (MRCC) iN Spain.
المؤلفون:	Espinosa J; Hospital General Universitario de Ciudad Real, Ciudad Real, Spain., González-Larriba JL; Hospital Clínico San Carlos, Madrid, Spain., Maroto P; Hospital Sant Pau, Barcelona, Spain., Méndez-Vidal MJ; Hospital Reina Sofía, Córdoba, Spain., Díaz-Cerezo S; GSK España, Tres Cantos, Spain.
المصدر:	Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2014 Nov; Vol. 17 (7), pp. A632-3. Date of Electronic Publication: 2014 Oct 26.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Elsevier Country of Publication: United States NLM ID: 100883818 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1524-4733 (Electronic) Linking ISSN: 10983015 NLM ISO Abbreviation: Value Health Subsets: PubMed not MEDLINE
أسماء مطبوعة:	Publication: Jan./Feb. 2011- : New York : Elsevier Original Publication: Malden, MA : Blackwell Science, c1998-
تواريخ الأحداث:	Date Created: 20160521 Date Completed: 20160610 Latest Revision: 20160521
رمز التحديث:	20231215
DOI:	10.1016/j.jval.2014.08.2265
PMID:	27202249
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	1524-4733
DOI:	10.1016/j.jval.2014.08.2265